Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Bites and Stings × Hydroxyurea × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 5 Gliosarcoma 4 Squamous Cell Carcinoma of Head and Neck 3 Glioma 3 Brain Neoplasms 3 Salivary Gland Neoplasms 2 Central Nervous System Neoplasms 2 Treatment-Refractory Solid Tumors 1 Tongue Neoplasms 1 Oligodendroglioma 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 HPV-Negative Squamous Cell Carcinoma 1 Esthesioneuroblastoma, Olfactory 1 Ependymoma 1 Carcinoma, Non-Small-Cell Lung 1 Bites and Stings 1 Astrocytoma 1 Advanced Solid Tumors 1

Interventions

pembrolizumab 3 blinatumomab 2 enzalutamide 1 durvalumab 1 dostarlimab 1 cemiplimab 1 atezolizumab 1 abiraterone 1 N,N-dicyclohexyl-isoborneol-10-sulfonamide 1 Immune Checkpoint Inhibitors 1 Hydroxyurea 1 Etoposide 1 Etanercept 1 Cytochrome P-450 Enzyme System 1 Carboplatin 1 AMG 757 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06063317 2026-03-06

OASIS

Imugene Limited

Phase 1 Terminated

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon ⚡